# Sanofi: overview SNY · Nasdaq · CIK 1121404 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/sny.md) · [Financials](/companies/sny/financials.md) · [Filings](/companies/sny/filings.md) · [Insiders](/companies/sny/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | [6.66](/filings/0001121404-25-000010.md) | [4.30](/filings/0001628280-26-008403.md) | [4.43](/filings/0001628280-26-008403.md) | [6.37](/filings/0001628280-26-008403.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sny/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Dodge & Cox](/funds/200217.md) | 2026-06-30 | $1.20bn | 28,088,274 | | Reduced −1,416,358 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $456.6m | 10,702,527 | | Reduced −1,809,340 | | [Fisher Asset Management, LLC](/funds/850529.md) | 2026-06-30 | $453.4m | 10,627,088 | | Reduced −815,075 | | [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $341.6m | 8,008,572 | | Reduced −1,475,778 | | [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $290.0m | 6,798,961 | | Added +177,422 | | [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $285.5m | 6,573,682 | | Added +972,951 | | [Mondrian Investment Partners LTD](/funds/1317724.md) | 2026-06-30 | $235.6m | 5,522,564 | | Added +482,499 | | [BRANDES INVESTMENT PARTNERS, LP](/funds/1015079.md) | 2026-06-30 | $176.5m | 4,136,417 | | Added +413,317 | | [FEDERATED HERMES, INC.](/funds/1056288.md) | 2026-06-30 | $164.2m | 3,849,802 | | Reduced −904,557 | | [Boston Partners](/funds/1386060.md) | 2026-06-30 | $164.0m | 3,844,844 | | Added +245,560 | ## Recent filings [All 991 filings](/companies/sny/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-30 | 08:49 ET | [6-K](/filings/0001121404-26-000009.md) | Report of a foreign private issuer, period 2026-09-30 | 0001121404-26-000009 | | 2026-10-26 | 06:41 ET | [6-K](/filings/0001193125-26-431012.md) | Report of a foreign private issuer, period 2026-10-26 | 0001193125-26-431012 | | 2026-10-01 | 12:09 ET | [6-K](/filings/0001193125-26-410232.md) | Report of a foreign private issuer, period 2026-10-01 | 0001193125-26-410232 | | 2026-09-17 | 06:09 ET | [6-K](/filings/0001193125-26-393653.md) | Report of a foreign private issuer, period 2026-09-17 | 0001193125-26-393653 | | 2026-08-06 | 06:02 ET | [6-K](/filings/0001193125-26-336497.md) | Report of a foreign private issuer, period 2026-08-06 | 0001193125-26-336497 | | 2026-07-30 | 07:34 ET | [6-K](/filings/0001628280-26-050803.md) | Report of a foreign private issuer, period 2026-06-30 | 0001628280-26-050803 | | 2026-07-30 | 06:28 ET | [6-K](/filings/0001121404-26-000008.md) | Report of a foreign private issuer, period 2026-06-30 | 0001121404-26-000008 | | 2026-07-27 | 06:10 ET | [6-K](/filings/0001193125-26-316771.md) | Report of a foreign private issuer, period 2026-07-27 | 0001193125-26-316771 | | 2026-07-17 | 06:02 ET | [6-K](/filings/0001193125-26-306689.md) | Report of a foreign private issuer, period 2026-07-17 | 0001193125-26-306689 | | 2026-07-07 | 09:02 ET | [6-K](/filings/0001193125-26-296990.md) | Report of a foreign private issuer, period 2026-07-07 | 0001193125-26-296990 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-008403.md), filed Feb 17, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1121404 - Tickers: SNY, SNYNF - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: I0 - Filer category: Large accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 08:51 ET. No prices; not investment advice.